The inhibitors work by aiming two DNA repair systems at the same time, killing cancer cells while evading the healthy cells.

Toll-Free National Educational Teleconference for Women with Ovarian Cancer on Sept. 21, 2011. Featuring Dr. Afshin Bahador, a board certified Obstetrician and Gynecologist with subspecialty board certification in Gynecologic Oncology.

The study is a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

Support Connection, Inc. is still accepting registration for their 16th Annual Support-A-Walk for breast & ovarian cancer. Advance registration is recommended; more than 9,000 people attended in 2009.

Pre-registration hours for the Support-A-Walk for breast & ovarian cancer have begun. Pre-registration is recommended. Close to 10,000 people attended this event last year.

The Study Chair will be Dr. David E. Cohn of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

For women with ovarian cancer: A toll-free teleconference presentation & discussion with Dr. Thomas J. Herzog of Columbia University Herbert Irving Comprehensive Cancer Center at The New York-Presbyterian Hospital. Free.

Researchers are hopeful that a biologic therapy called Reolysin will extend the lives of thousands of women stricken with ovarian cancer.

The International Federation of Gynecology and Obstetrics (FIGO) launched a major component in the fight to control cervical cancer on 8 October 2009, releasing its global guidance document and announcing a unique partnership with the International P